[June 24, 2015]

Research and Markets: Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C Therapeutics Pipeline Review, H1 2015 - 4 Companies & 9 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/f5j32v/acid) has announced the addition of the "Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ad press releases. It also reviews key players involved in the therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• La Jolla Pharmaceutical Company
• Merck & Co., Inc.
• Okklo Life Sciences BV
• Orphazyme ApS

Drug Profiles

• arimoclomol
• Bryostatin-1
• Delta-tocopherol
• LJPC-0712
• ML-SA1
• OKL-1014
• OR-0005
• vorinostat
• VTS-270

For more information visit http://www.researchandmarkets.com/research/f5j32v/acid

View source version on businesswire.com: http://www.businesswire.com/news/home/20150624006099/en/

[ Back To TMCnet.com's Homepage ]